Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)
Longeveron's (LGVN) quarterly Cash from Financing Activities came in at $15.5 million in Q1 2026, up 26801.72% year-on-year from N/an in Q1 2025, and up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025.
Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 29.49% decrease from a year earlier, with the FY2025 full-year figure at $4.7 million, down 83.78% from the prior year.
- Cash from Financing Activities rose to $15.5 million in Q1 2026 per LGVN's latest filing, from $777000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $15.5 million in Q1 2026 and bottomed at -$193000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is -$27000.0 (2022), against an average of $3.2 million.
- Across the five-year window, Cash from Financing Activities sank 678.95% in 2022 and surged 27548.0% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at -$193000.0 in 2022, then soared by 2905.7% to $5.4 million in 2023, then slumped by 100.92% to -$50000.0 in 2024, then surged by 1654.0% to $777000.0 in 2025, then soared by 1893.18% to $15.5 million in 2026.
- Per Business Quant, the three latest LGVN Cash from Financing Activities figures stand at $15.5 million (Q1 2026), $777000.0 (Q4 2025), and $4.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 15.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.49 Mn |
| Mar 31, 2026 | 15.49 Mn |
| Dec 31, 2025 | 777,000.00 |
| Dec 31, 2025 | 777,000.00 |
| Sep 30, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | -133,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Sep 30, 2024 | 13.72 Mn |
| Sep 30, 2024 | 13.72 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 5.42 Mn |
| Dec 31, 2023 | 5.42 Mn |